Tang et al. propose the use of a small molecule compound D6 to treat EGFRTKI resistant tumors. The authors demonstrate potent and selective inhibition of NSCLC with T790M-mediated EGFR-TKI resistance through inhibiting HSP90-mediated protein–protein interaction.
- Xiaolong Tang
- Lizhi Cheng
- Baohua Liu
